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Growth factors and their cell-surface receptors play important roles in metazoan 
signaling, contributing to both normal development and the progression of disease.  The 
past few decades have witnessed considerable advancement in our understanding of how 
one class of transmembrane receptors, the receptor tyrosine kinases (RTKs), transduce 
signals across the membrane. Biochemical investigation of isolated components of the 
receptors, as well as studies of receptors expressed in cultured cells, have revealed key 
features of the mechanisms that regulate receptor autoinhibition and ligand-induced 
activation. With few exceptions, all RTKs are composed of an extracellular ligand-
binding domain, a single transmembrane alpha-helix, and an intracellular tyrosine kinase 
domain.  Receptors exist on the plasma membrane in equilibrium between monomers and 
oligomers, and ligand binding to the extracellular domains promotes the formation of 
active oligomers or induces conformational rearrangement within ligand-independent 
oligomers, or both.  Once activated, the tyrosine kinase domains phosphorylate their 
receptor dimer partners as well as downstream cytosolic substrates, thus propagating 
transduction of the signal. 
 Despite this considerable progress, the models derived from biochemical studies 
of purified receptor components fail to explain important features of receptor function in 
cells, such as (i) the existence of negative cooperativity in receptor-ligand binding and (ii) 
the existence of ligand-independent oligomers (Lemmon, 2009) (Endres, et al., 2014).  In 




Dimerization is required for receptors to become activated, but dimerization itself is not 
sufficient to fully activate the kinase domains.   
Much of the uncertainty surrounding receptor function may arise due to a dearth 
of structural and biochemical studies of receptors embedded in a native bilayer 
environment.  To address these issues, we employed a variety of biochemical and 
biophysical methods to investigate the relationship between receptor dimer formation and 
receptor activation in two types of RTKs: the epidermal growth factor receptors 
(EGFR/ErbB) and the insulin/insulin-like growth factor receptor (IR/IGF1R).  
Biochemical studies of receptor function in cultured cells allowed us to compare the 
signaling characteristics of wild-type and genetically-modified receptors.  Mutational 
analysis revealed regions of receptor that are important for both receptor autoinhibition 
and kinase activation.  We then used quantitative imaging confocal FRET microscopy 
(QI-FRET) to investigate the relationship between receptor oligomerization and receptor 
activation.  For both ErbBs and IGF1R, we observed that isolated transmembrane 
domains tend to form strong dimers, and that the extracellular domains impede intrinsic 
TM domain interactions.  Ligand binding relieves ECD autoinhibition, allowing for TM 
association. 
For the ErbB family, our results indicate that dimer formation depends upon 
receptor concentration in the membrane, with the intracellular domain promoting dimer 
formation in the absence of ligand.  Increased levels of ErbB1 cell surface expression 
correlate with low levels of ligand-independent kinase activity.  Moreover, the expression 




dimerization constant determined from FRET experiments.  Unliganded EGFR dimers 
therefore form according the law of mass action, and are likely populated by a mixture of 
active and inactive states.  The receptor thus follows one of two possible mechanisms 
upon ligand binding, depending on the receptor surface density: a switch from inactive 
monomers to active dimers in the low expression regime, and a transition from inactive to 
active dimers in the high expression regime.  Taken together, these studies have 
identified transmembrane separation as an important determinant of RTK dimer activity, 
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Chapter 1.  A single ligand is sufficient to activate EGFR 
dimers 
Note to reader: This chapter comprises excerpts from the following reference: (Liu, et al., 
2012).  It has been edited for clarity. 
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Abstract 
Crystal structures of human epidermal growth factor receptor (EGFR) with bound 
ligand revealed symmetric, doubly ligated receptor dimers thought to represent 
physiologically active states. Such complexes fail to rationalize negative cooperativity of 
epidermal growth factor (EGF) binding to EGFR and the behavior of the ligandless 
EGFR homolog ErbB2/HER2, however. We report cell-based assays that provide 
evidence for active, singly ligated dimers of human EGFR and its homolog, 
ErbB4/HER4. 
Introduction 
Human epidermal growth factor receptor (EGFR) and its homologs, known as 




differentiation during animal development and are the targets of multiple cancer therapies 
(Burgess, 2008). EGFR is the archetype of single-pass membrane-spanning receptors 
thought to transmit signals by ligand-induced dimerization (Heldin, 1995) (Yarden & 
Schlessinger, 1987), and structural studies show that ligand binding to human EGFR 
promotes rearrangement of its four extracellular domains from a tethered to an extended 
conformation in which a loop, termed the dimerization arm, becomes exposed and 
mediates formation of symmetric receptor dimers (Burgess, 2003) (Fig 1.1A). At odds 
with a ligand-induced dimerization model of EGFR signaling, however, are recent studies 
showing dimers of human EGFR in the absence of ligand (Chung, et al., 2010) (Gadella 
& Jovin, 1995) (Moriki, et al., 2001) (Sako, et al., 2000) as well as negative cooperativity 
when epidermal growth factor (EGF) binds to EGFR (Macdonald & Pike, 2008). 
Curiously, the single Drosophila EGFR homolog adopts an extended conformation in the 
absence of ligand and forms asymmetric receptor dimers with a single high-affinity 
ligand bound (Alvarado, et al., 2010) (Zhang, et al., 2010), suggesting different 
mechanisms may regulate EGFR activation in Drosophila and humans. 
We report here evidence for active, singly ligated homodimers of human EGFR 
and its homolog, ErbB4. These results compel reappraisal of canonical views of ligand-
induced dimerization and show that several previously anomalous properties of human 
EGFR and its homologs represent vertebrate innovations on a core signaling mechanism 




Results and Discussion 
We reasoned that if singly ligated dimers of human EGFR exist as implied by 
negative cooperativity (Macdonald & Pike, 2008), an EGFR variant incapable of binding 
ligand may remain able to participate in signaling dimers. To test this idea, we introduced 
debilitating amino-acid substitutions into the ligand-binding site of one EGFR variant and 
the kinase active site of another. These variants show negligible ligand-dependent 
phosphorylation when expressed individually in CHO cells, but co-expression restores 
phosphorylation in response to ligand as judged by both general and specific anti-
phosphotyrosine antibodies (Fig. 1.1B and Table 1.1). The simplest explanation for this 
observation is that ligand-binding deficient receptors are able to pair with kinase-
deficient receptors to form active, singly ligated EGFR dimers. Similar results were 
obtained for ErbB4/HER4 (Fig. 1.1C). Amino-acid substitutions in the ErbB4 
dimerization arm in the context of either ligand-binding or kinase-activity deficient 
ErbB4 variants eliminates responsiveness when co-transfected, implicating dimerization 
arms from both partners in formation of singly ligated ErbB4 dimers. Participation of 
unliganded ErbBs in a signaling dimer despite burial of the dimerization arm in the 
tethered conformation likely reflects favorable energetics of the inter-receptor dimer 
interface relative to the tethered state within a preformed dimer. 
An essential feature of EGFR activation is an asymmetric dimer of EGFR kinase 
domains in which the C-terminal region of a “donor” kinase contacts the N-terminal 
region of an “acceptor” kinase and stimulates it (Zhang, et al., 2010) (Fig. 1.1A), and the 




coupled to this intracellular asymmetry. The ability of ligand-binding deficient EGFR to 
be activated by kinase-dead EGFR demonstrates that unliganded EGFRs can function as 
the acceptor kinase (Fig. 1.1B). To determine if ligand-binding deficient EGFR can 
function as a donor kinase, debilitating amino-acid substitutions were simultaneously 
introduced into the ligand-binding and kinase active sites of one EGFR and into the 
kinase donor site of another EGFR. Neither variant showed ligand-dependent 
phosphorylation when expressed on its own, but weak, ligand-dependent phosphorylation 
was observed when co-expressed (Fig. 1.1B). Similar results were obtained for ErbB4 
(Fig. 1.1C). This observation suggests that unliganded EGFRs can serve as both a donor 
and an acceptor kinase and that extracellular asymmetry is not absolutely coupled to 
intracellular asymmetry, consistent with studies suggesting a loose linkage between 
ligand binding and kinase activation (Lu, 2010). A recent report using a luciferase 
fragment complementation assay showed that normal activation of EGFR/ErbB2 
heterodimers required the EGFR kinase to be active, suggesting that the liganded partner 
(EGFR) could initially only function as an acceptor kinase and that extra- and 
intracellular asymmetry are coupled (Macdonald-Obermann, et al., 2012). In this case the 
intracellular kinases differ (vs. EGFR or ErbB4 homodimers), which may contribute to 
additional stabilization of the EGFR kinase in the acceptor role in the absence of 
phosphorylation. It will be interesting to determine if this is indeed the case or whether 
other factors underlie this apparent difference. The sites of all tested amino-acid 
substitutions are listed in Table 1.1. None of these sites impaired cell surface expression 




Western blot (Table 1.2, Fig. 1.2). Curiously, an original ligand-binding mutation 
introduced in EGFR, D355R, failed to express on the cell surface unless co-transfected 
with kinase-deficient EGFR. This observation suggests that EGFR molecules interact 
early in biogenesis and that this interaction can rescue otherwise nonviable forms of 
EGFR. 
Participation of unliganded ErbBs in active signaling complexes prompts 
reassessment of the role of the tethered conformation, which was first interpreted as 
keeping ErbBs “off” in the absence of ligand (Burgess, 2003) (Cho & Leahy, 2002) 
(Ferguson, et al., 2003). It is now apparent that the straight conformation of domain II is 
sufficient for this purpose, as evidenced by the absence of a tethered conformation in 
Drosophila EGFR and the failure of tether mutations in human EGFR to result in 
receptor activation (Alvarado, et al., 2010) (Mattoon, et al., 2004) (Walker, et al., 2004). 
In an organism with multiple EGFR homologs, however, the ability of an unliganded 
ErbB to participate in a signaling complex means that ligand binding to any ErbB could 
activate all coexpressed ErbBs. Such promiscuous activation is observed for 
ErbB2/HER2, for example, which is the only vertebrate ErbB not to adopt a tethered 
conformation. An additional inhibitory mechanism was thus needed to prevent 
indiscriminate ErbB responses to individual ligands in species with multiple ErbB 
homologs. By precluding unliganded EGFR, ErbB3, or ErbB4 from pairing with liganded 
forms of other ErbBs, the tethered conformation fulfills this role and likely facilitated 
diversification of ErbB function. The tethered conformation of human EGFR (Ferguson, 




fixed, ligandless conformation of ErbB2 (Cho, et al., 2003) (Garrett, et al., 2003) thus 
appear to have arisen following the appearance of multiple ErbB homologs as 
elaborations on the core signaling mechanism present in Drosophila EGFR. As tethered 
ErbBs appear able to convert to a signaling competent extended-straight conformation 
when dimerized with a liganded partner, which ErbB dimers form in the absence of 
ligand will govern the nature of ErbB responses and is an important avenue for future 
investigation. The stability of doubly-ligated ErbBs may have arisen to allow 
heterodimerization of ErbBs when ligands for both are present. 
ErbBs have evolved many mechanisms to safeguard and modulate their potent 
activity. The presence of inactive, singly ligated, and doubly ligated human ErbB dimers 
confers several advantages over a ligand-induced dimerization activation mechanism. 
Inactive dimers present a barrier to activation through random dimerization, and the 
presence of singly and doubly ligated dimers furnishes a mechanism to tune responses to 
different concentrations or affinities of ligands (Alvarado, et al., 2010). The results 
presented here show how specific intra- and intermolecular conformations combine to 
govern ErbB activity and lead to a unifying model of ErbB activation that rationalizes 
previously puzzling properties of EGFR and its homologs. 
Materials and Methods 
Generation of ErbB-expressing Cell Lines 
Genes encoding ErbB mutants were generated by QuikChange mutagenesis 




subcloned with their native signal sequences into pSSX, a version of pSGHV0 modified 
to eliminate the growth hormone tag and add C-terminal Flag or HA tags (Leahy, et al., 
2000). CHO-S cells (Invitrogen) were maintained in adherent culture in DMEM:F12 
supplemented with 5% FBS. Stably transfected cell lines were created using FuGENE 
(Roche) according to manufacturer’s instructions. Cells were cotransfected with a total of 
1 μg DNA per ml culture and 0.1 μg per ml of pCDNA 3.1 (Invitrogen), which contains 
the neomycin resistance gene. After 24 hours, fresh medium containing 1 mg/ml G418 
was added, and the cells fed every three days until colonies appeared. Colonies were 
picked, expanded, and screened for ErbB expression by Western using the appropriate tag 
antibody.  
Antibodies used for immunoprecipitation or Western detection were Flag-M2 
(Sigma), 3F10 anti-HA (Roche), anti-EGFR (Santa Cruz sc-71033), anti-EGFR pY1068 
(Abcam EP774Y), anti-ErbB4 (Santa Cruz sc-283), and 4G10 antiphosphotyrosine 
(Millipore). The number of receptors per cell was estimated by comparison of anti-EGFR 
band intensities of cell lysates compared to intensities of known amounts of purified 
tEGFR (Qiu, et al., 2009); cell lines with approximately equal expression of the ErbB 
variants were chosen for stimulation assays. 
ErbB Activity Assays 
ErbB-expressing cell lines were plated in 2 wells of a six-well plate at 
0.2 × 106 cells per well and grown 24 hr. On the day of the assay, cells were washed three 
times with 2 ml Ham’s F12 supplemented with 1 mg/ml BSA, then serum-starved for at 




wells at a final concentration of 100 ng ml-1, and the plates incubated at 37 °C for 
5 minutes. The wells were then washed once with ice-cold phosphate-buffered saline, and 
250 μl of RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS) supplemented with 1 mM activated Na3VO4, 1 mM PMSF, 
and Benzonase nuclease (Sigma) was added directly to the wells. The cells were allowed 
to lyse for 30 minutes with gentle rocking, and the appropriate antibody was added to the 
lysate (using 0.5 μg/ml for anti-Flag and 0.1 μg/ml for anti-HA). Lysates were next added 
directly to 20 μl Protein G Sepharose 4 Fast Flow (GE), and allowed to bind overnight at 
4 °C. Finally, beads were washed 3 times with 1 ml of RIPA buffer supplemented with 
1 mM activated Na3VO4 and eluted by adding 20 μl of 5× SDS-PAGE loading buffer 
containing 10% fresh β-mercaptoethanol and incubating for 30 minutes at room 
temperature. Eluted proteins were separated on 4% to 20% Tris-Glycine SDS-PAGE gels 
(Invitrogen), transferred to PVDF membranes, and probed with the antiphosphotyrosine 
antibody 4G10. A portion of crude lysate was reserved, run separately, and probed with 










Figure 1.1 Evidence for singly ligated ErbB signaling dimers 
 
 
Figure 1.1. Evidence for singly ligated ErbB signaling dimers. (A) Schematic diagram 
showing tethered, extended, and dimeric conformations of EGFR with sites of function-
targeting mutations indicated. (B) Anti-phosphotyrosine and anti-EGFR Western blots of 
tagged full-length EGFR immunoprecipitated from stably transfected CHO cells. Wild-
type (WT) EGFR was tagged with either hemagglutinin (HA) or Flag peptides, EGFR 
bearing an inactivating mutation in its kinase active site (Kin-) was tagged with HA, and 
EGFR bearing a mutation in its ligand-binding site (Lig-) was tagged with Flag. Mutation 
in the Kinase donor site (Do-) and combination of the Kinase- and Ligand-targeting 
mutations on a single EGFR (Kin-: Lig-) were also tested. Serum-starved cells were either 
untreated (−) or treated (+) with EGF for 5 minutes. Each WT or mutant EGFR was 
transfected singly; the Kin- and Lig- variant EGFRs were co-transfected as were the (Kin-
: Lig-) and (Do-) variants. When co-transfected, the tag used for immunoprecipitation 
prior to Western blotting is indicated in red. (C) Similar experiments using ErbB4 and its 




rearranged electronically to match the order of experiments in (B). Bar graphs represent 






































Figure 1.2 Quantification of EGFR expression in CHO stable cell lines 
 
Figure 1.2 Anti-EGFR Western blots of lysates from known numbers of the EGFR-
transfected cells used in cell-based assays, as well as A431 cells. Cell lines are labeled as 
in Figure 1.1. Known amounts of purified, truncated EGFR were loaded as standards 




































Chapter 2:  How IGF-1 activates its receptor 
Note to reader: this chapter contains excerpts from (Kavran, et al., 2014).  It has been 
edited for clarity where appropriate. 
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Abstract 
The type I insulin-like growth factor receptor (IGF1R) is involved in growth and 
survival of normal and neoplastic cells. A ligand-dependent conformational change is 
thought to regulate IGF1R activity, but the nature of this change is unclear. We point out 
an underappreciated dimer in the crystal structure of the related Insulin Receptor (IR) 
with Insulin bound that allows direct comparison with unliganded IR and suggests a 
mechanism by which ligand regulates IR/IGF1R activity. We test this mechanism in a 
series of biochemical and biophysical assays and find the IGF1R ectodomain maintains 
an autoinhibited state in which the TMs are held apart. Ligand binding releases this 




intracellular regions to autophosphorylate. Enzymatic studies of full-length and kinase-
containing fragments show phosphorylated IGF1R is fully active independent of ligand 
and the extracellular-TM regions. The key step triggered by ligand binding is thus 
autophosphorylation. 
Introduction 
The insulin and type-1 insulin-like growth factor receptors (IR and IGF1R) are 
homologous receptor tyrosine kinases (RTKs) that regulate cell metabolism, growth, and 
differentiation in a variety of mammalian tissues (De Meyts, 2004) (Siddle, 2011) 
(Siddle, 2012). Each is essential for normal development (Liu, et al., 1993) (Accili, et al.,, 
1996), and abnormal IR or IGF1R signaling is associated with many disorders, notably 
diabetes and cancer (De Meyts & Whittaker, 2002) (Pollak, 2012). Although IGF1R is 
mainly associated with cell growth and differentiation and IR with regulation of glucose 
and lipid metabolism (Siddle, 2012), IGF1R and IR share 58% sequence identity and 
appear to signal via largely conserved molecular mechanisms (Siddle, 2011) (Ward, et 
al., 2013). 
IR and IGF1R are disulfide-linked homodimers of single-pass integral membrane 
protein subunits. Each subunit undergoes a furin-like cleavage into α and β chains that 
remain disulfide-linked and are composed of six extracellular domains (L1, CR, L2, Fn1, 
Fn2, and Fn3) followed by a transmembrane (TM) region, a ∼30 amino acid 
juxtamembrane region, a tyrosine kinase domain, and a C-terminal tail (Ullrich, et al.,, 




insertion in Fn2, termed the insert domain (ID), contains the cleavage site and three 
cysteines of which one or more form reciprocal inter-subunit disulfide bonds. An 
additional inter-subunit disulfide is formed between cysteines in Fn1 (Cheatham, et al., 
1993) (Schaffer & Ljungqvist, 1992) (Sparrow, et al., 1997). 
Ligand binding to IR and IGF1R extracellular regions (ECDs) stimulates receptor 
kinase activity, leading to phosphorylation of multiple substrates and initiation of specific 
signaling cascades (Siddle, 2012). IR family members are unique among RTKs in 
forming constitutive dimers (of αβ subunits). Dimerization per se thus cannot be the 
activating signal, and activation is thought to involve a ligand-dependent conformational 
change (Frattali, et al., 1992) (Lemmon & Schlessinger, 2010). Part of the function of the 
ECD appears to be maintaining an inactive state in the absence of ligand as tryptic 
removal of the IR ECD results in constitutive activity (Tamura, et al., 1983) (Shoelson, et 
al., 1988). 
Two ligand-binding sites are present in each αβ dimer. Each site is composed of 
two distinct partial sites known as ‘Site 1’, which is composed of residues on L1 from 
one subunit and residues on the αCT′ helix of the other subunit (a prime is used to 
indicate the opposite subunit), and ‘Site 2’, which is composed of residues on Fn1′ and 
Fn2′ (Williams, et al., 1995) (Mynarcik, et al., 1996) (Whittaker, et al., 2001) (Whittaker, 
L, et al., 2008) (Smith, et al., 2010). A classic feature of ligand binding to IR and IGF1R 
is negative cooperativity (De Meyts, 2004), which implies communication between the 




receptor in which the affinity of the second site for ligand is weakened. The nature of this 
asymmetric state is not known, but hydrogen–deuterium exchange experiments with 
IGF1R identified regions that are likely foci of this asymmetry (Houde & Demarest, 
2011). 
To address the gaps in our understanding of the molecular mechanisms 
underlying IR family activation, we performed a series of biochemical and biophysical 
assays and show that the IGF1R ECD indeed autoinhibits activity by holding the TMs 
apart in the absence of ligand. Ligand binding releases this autoinhibition and allows the 
TMs to come together in an autophosphorylation-competent state. The key step regulated 
by ligand binding is thus autophosphorylation and not kinase activity per se, and the role 
of the IR/IGF1R ECD is to inhibit activity in the absence of ligand rather than promote 
activity in the presence of ligand. 
Results 
Release of IGF1R autoinhibition by ligand brings the TMs together 
Loss of either the L1 domain or the ECD eliminates the inter-subunit interaction 
between L1:Fn2′–3′ that fixes the separation of the TM regions (Kavran, et al., 2014). To 
examine if TM separation is altered in active receptors, we replaced the intracellular 
domain (ICD) of IGF1R with fluorescent donor or acceptor proteins (IGF1R ECD-TM-
fp) and determined the FRET efficiency between co-transfected donor–acceptor pairs in 
the presence and absence of ligand (Figure 2.3). We used spectrally resolved Förster 




at the pixel level in transfected CHO cells, which ensures only proteins expressed at the 
cell membrane are included in the analysis. FRET efficiency increased twofold in the 
presence of ligand (Figure 2.3A). Assuming comparable if not random orientations of the 
fluorescent proteins in both states, these data indicate the C-termini of the TMs move 
closer together in the presence of ligand. A similar increase in FRET efficiency was 
observed in vesicles derived from CHO cells expressing IGF1R ECD-TM-fp in the 
presence and absence of ligand (Figure 2.4). We also measured the FRET efficiency for 
IGF1R lacking the L1 domain (IGF1R ECDΔL1-TM-fp) and found that its FRET 
efficiency is similar to that of IGF1R ECD-TM-fp with bound ligand suggesting that the 
ligand bound state of IGF1R is similar to that of the receptor when the L1:Fn2′–3′ 
interface is disrupted (Fig. 2.4). 
If the IGF1R ECD inhibits IGF1R activity by enforcing TM separation, 
introduction of flexible linkers between the ECD and TM regions should release this 
inhibition, and insertion of progressively longer linkers composed of glycine–serine 
containing repeats between 4 and 20 residues long indeed led to increasing levels of basal 
receptor activity (Figure 2.3B). 
Isolated IGF1R TMs dimerize 
The ligand-dependent decrease in distance between IGF1R TMs observed in 
FRET assays of IGF1R ECD-TM-fp led to the question of whether IGF1R TMs 
physically associate in the active state. Analysis of IR family TM sequences failed to 




Engelman, 2000), but did identify an absolutely conserved proline (P911 in human 
IGF1R) (Figure 2.5A). To investigate the role of P911 in receptor activation, we 
performed cell based activity assays with IGF1R-fl bearing either a single P911L 
substitution or with additional substitutions to residues surrounding P911. These IGF1R 
variants became phosphorylated in a ligand-dependent manner suggesting P911 does not 
play a key role in mediating receptor activity, an outcome consistent with the results of 
earlier studies involving more dramatic manipulations of IR TM residues and suggesting 
lax constraints on TM sequence (Fratalli, et al., 1991) (Yamada, et al., 1992) (Cheatham, 
et al., 1993) (Figure 2.5). 
Experimental evidence that IGF1R TMs have an intrinsic propensity to dimerize 
in bilayers was obtained from quantitative imaging FRET (QI-FRET) experiments (Li, et 
al., 2008). Isolated IGF1R TMs were fused to C-terminal donor or acceptor fluorescent 
proteins (IGF1R TM-fp) and transiently transfected into CHO cells (Fig. 2.5). Vesicles 
containing variable amounts of expressed proteins were generated and FRET efficiency 
analyzed (Chen, et al., 2010a) (Del Piccolo, et al., 2012).  FRET efficiency increased as a 
function of fluorescent protein concentration and exceeded the theoretical levels of FRET 
expected to arise from random proximity (King, et al., 2014), demonstrating an intrinsic 
propensity of IGF1R TMs to associate (Figure 2.5C). 
An intrinsic propensity of IGF1R TM and ICD regions to dimerize was also 
demonstrated by cysteine substitutions in constitutively active ECD-truncated forms of 




proximal residue H905 approach within 6 Å of one another in the MD dimer (Figure 
2.5B), and H905 or T898 were individually substituted with cysteine in IGF1R TM-icd 
variants. Western blots of reduced and non-reduced lysates from HEK293 cells 
expressing these proteins show that the majority of the H905C variant forms a disulfide-
linked dimer (Figure 2.5D). Lower amounts of dimerization were observed for the T898 
variant in which the cysteines are farther away from the TM region (Figure 2.5D), and no 
disulfide crosslinking was observed for an equivalently truncated IGF1R without a 
cysteine substitution. These results demonstrate that, in the absence of the ECD, the 
IGF1R TM-icds come together in a manner consistent with the MD TM dimer. 
IGF1R TMs dimerize in the active, full-length receptor 
We next investigated whether juxtamembrane cysteines formed disulfide 
crosslinks when introduced into IGF1R-fl (Figure 2.6A). We could not directly analyze 
intra-dimer disulfide bond formation by introduced cysteines by analyzing migration on 
reducing and non-reducing SDS-PAGE owing to the native disulfide bonds linking α and 
β chains. To circumvent this issue, we substituted the cysteine residues that mediate the 
αβ disulfide with serine. These substitutions inhibited proper proteolytic processing of the 
receptor, however, obscuring differentiation of the new disulfide bond from native 
disulfide bonds. To our surprise, however, Western blots monitoring the phosphorylation 
of the IGF1R variants with the single substitutions of either T898C or H905C revealed 
high levels of phosphorylation in the absence of ligand (Figure 2.6A). An IGF1R-fl 




away from the TM (Q895C) displayed only a modest increase in basal phosphorylation 
compared to wild-type (Figure 2.6A), perhaps owing to steric interference from Fn3 
domains. 
An intra-dimer disulfide between cysteines at position 905 would force TM 
association. When the H905C substitution was introduced into IGF1R ECD-TM-fp, the 
FRET efficiency of this variant in the absence of ligand matched that of native IGF1R 
ECD-TM-fp in the presence of ligand (Figure 2.6B). This result shows that the H905C 
substitution indeed leads to decreased TM separation, presumably owing to crosslinked 
juxtamembrane regions, and that this conformation is indistinguishable from that 
observed for liganded IGF1R ECD-TM-fp. 
Discussion 
We describe a molecular mechanism for IR/IGF1R activation in which ECD-
enforced separation of TMs maintains the receptor in an inhibited state. Ligand binding 
relieves this inhibition by disrupting the L1:Fn2′–3′ interaction that stabilizes TM 
separation, freeing the TMs to associate and autophosphorylation of the kinase domains 
to proceed (Figure 2.7). This model is based on a previously underappreciated dimer in 
the crystal structure of an Insulin bound IR ECD fragment, which provides a basis for 
comparing liganded and unliganded structures of the IR ECD. 
To validate this model, we present FRET and mutagenesis studies that 
demonstrate (i) a decrease in IGF1R TM separation when ligand binds, (ii) an intrinsic 




associated state, consistent with the increased activity of the IGF1R ICD when fused to a 
dimeric partner (Baer, et al.,, 2001) (iv) that the role of the ECD is primarily to inhibit 
this intrinsic kinase activity in the absence of ligand, rather than promote a specific active 
state, (v) that IGF1R TMs associate in an active form of the full-length receptor, and (vi) 
that IGF1R samples the active state even in the absence of ligand. Enzymatic studies of 
full-length IGF1R and IGF1R fragments further demonstrate no role for allostery in 
maintaining IGF1R activity once it is phosphorylated, indicating that the key step 
regulated by ligand binding is autophosphorylation. Although ligand binding has no 
effect on the intrinsic activity of phosphorylated IGF1R, the short half-life of IGF1R 
phosphorylation when phosphatases are present suggests the continued presence of ligand 
may be needed to maintain IGF1R activity (Kleiman, 2011). This efficiency of cellular 
phosphatases may also explain why transient sampling of the active state by IGF1R does 
not lead to constitutive activity. 
Previous models for IR activation have posited only modest changes in receptor 
conformation when ligand binds and that ‘twist’ rather than lateral movement of the Fn2–
3 domains is the activating signal or that the TM regions move from associated to apart 
during IR activation (Ward, et al., 2013) (Lee, et al., 2014). We show here that ligand 
binding to IGF1R leads to TM association. Thus the Fn2–3 domains must undergo a large 
movement upon ligand binding to accommodate the new position of the TMs. To model 
this movement, we appended the Fn2–3 tandems from the unliganded IR ECD structure 
to the structure of the IR ECD fragment bound to Insulin. The Fn2–3 tandems were then 




‘legs’ must be compatible with the TM dimer observed in MD simulations and that the 
residues on Fn2 that compose Site 2 contact ligand. Assuming the connection between 
Fn1 and Fn2 to be flexible (it buries ∼500 Å2 of surface area) and the Fn2–3 tandem to 
be rigid, we find it possible to place the Fn2–3 tandems so that Site 2 residues appose 
ligand and that the ECD C-termini are compatible with TM dimerization (Figure 2.7B–
D). 
We have modeled IR/IGF1R with two bound ligands (Figure 2.7D) but receptors 
with a single ligand bound may represent an important active state. Negative 
cooperativity implies that ligand binding at one site influences assembly of the second 
site. The most likely conduit of information between sites is through the αCTs, which are 
connected by an inter-subunit disulfide bond 8 residues from their N-termini. The αCTs 
are 30 Å farther apart in the liganded IR structure than in the unliganded IR structure 
(Smith, et al., 2010) (Menting, et al., 2013).  This increased separation is only possible 
because the inter-subunit disulfides that link the αCTs were deleted in the crystallized 
fragment of IR. In an intact receptor, the altered position of αCT following binding of one 
ligand would restrict the reach of the opposite αCT, likely hindering assembly of the 
second binding site and contributing to negative cooperativity. 
The intrinsic propensity of the TMs to associate may also contribute to negative 
cooperativity. Disruption of the L1:Fn2′–3′ interaction by ligand binding removes a 
restraint on the relative position of the TMs that served as a barrier to TM association 




of the L1′:Fn2–3 interaction at the unliganded site and the intrinsic propensity of the TMs 
to associate and couple TM association to rearrangement of elements of the unliganded 
binding site. This mechanism may underlie the restoration of negative cooperativity of 
soluble IR ECDs when their C-termini are artificially tethered (Hoyne, 2000). 
The results discussed so far implicate ECD-enforced TM separation as a key 
feature maintaining IGF1R and IR inactive states. The question then arises of how TM 
separation maintains the kinases in an inactive state. The simplest explanation is that 
spatial separation is sufficient to preclude one kinase from phosphorylating the other. The 
N-termini of subunits of an IGF1R kinase dimer captured in an apparent trans 
phosphorylation state are ∼50 Å apart (Wu et al., 2008), however, and the 27 residues 
separating each kinase domain from its TM could easily span the distance needed to 
reach the ∼120 Å separation imposed by the ECD. The IGF1R intracellular 
juxtamembrane regions must thus adopt some structure in the inactive state to preclude 
autophosphorylation, but secondary structure prediction algorithms only identify a short 7 
amino-acid β strand in this region. Outside of three positively charged residues 
immediately following the TM, no conserved regions of positive charge comparable to 
the region in EGFR thought to mediate interactions with the membrane are present (Jura, 
2009). Conversely, the fourfold enhancement of kinase activity when the juxtamembrane 
region is present implies some structure in this region in the active state. Attempts to 
identify regions of the IGF1R kinase important for maintaining the inactive state by 
either mutagenesis or inspection of kinase crystal lattices for a repeated interaction 




activity, and no repeated interactions or regions of positive charge are apparent in IGF1R 
kinase crystals that could mediate self interactions or interactions with the plasma 
membrane as has been proposed for EGFR (Arkhipov, et al., 2013). 
In contrast, the absence of allosteric enhancement of the activity of 
phosphorylated IGF1R implies the absence of a stable interaction between kinase 
domains in the active state. Consistent with this conclusion, surface mutagenesis of the 
IGF1R kinase demonstrates the absence of an EGFR-like asymmetric kinase dimer. 
Absence of allostery in the active state may be a general feature of RTKs whose activity 
is enhanced by multiple activation loop phosphorylations, including FGFR, Met, 
VEGFR, Alk, MUSK, Kit, and their homologs (Lemmon & Schlessinger, 2010). 
Transient intermediate states may direct the order of tyrosines phosphorylated, as 
observed for FGFR (Lew, et al., 2009), but once fully phosphorylated we suspect the 
activity of these kinases will also prove independent of allosteric stimulation. This 
behavior contrasts with that of EGFR, which relies on allostery via a kinase asymmetric 
dimer for activation rather than phosphorylation of the activation loop (Zhang, et al., 
2006). 
Although IGF1R ICDs do not appear to form a stable interaction in the active 
state, TM dimerization does appear to occur upon ligand binding. This observation is 
consistent with previous studies demonstrating a coupling between ligand binding and 
association of IR ECD C-termini as well as results with chimeric receptors. When the IR 




length IR, but when the C-termini of the ECD are fused to either a leucine zipper (Hoyne, 
2000) or an immunoglobulin Fc region (Bass, et al., 1996), high-affinity, native-like 
ligand binding is restored (Schaffer, 1994). TM dimerization is thus not only consistent 
with high-affinity ligand binding but promotes it. Furthermore, a chimeric receptor with 
an IR ECD and an EGFR TM and ICD can be activated by Insulin (Reidel, et al., 1986). 
As EGFR activation involves TM dimerization (Endres, et al., 2013), the Insulin-bound 
IR ECD is also compatible with TM dimerization. 
We present here a new molecular model for regulation of IGF1R and IR activity. 
The key feature of this model is maintenance of an inactive state by ECD-enforced 
separation of the TMs in the absence of ligand. Ligand binding releases this constraint, 
resulting in TM association and unleashing of the intrinsic propensity of the kinase 
regions to autophosphorylate and activate. This model is consistent with recent crystal 
structures of the IR ECD and suggests that some structure in the intracellular region 
precludes autophosphorylation in the unliganded state of the receptor. Conversely, 
enzymatic studies show that once phosphorylated and active, no structure outside of the 
kinase and juxtamembrane regions is needed to stimulate full kinase activity. This model 
provides a simple molecular context for understanding several features of IR/IGF1R 
activation and suggests directions for future study. It also suggests that chimeric proteins 
with IR or IGF1R ECDs may prove valuable for assessing the role of TM separation in 
other signaling systems or as ligand-dependent activity switches when fused, for 




Materials and Methods 
Expression and purification of fluorescent proteins 
Plasmids encoding N-terminally hexa-histidine tagged EYFP, mCherry, or mTurquoise 
were transformed into Escherichia coli BL21(DE3) cells. Cultures were grown in Luria 
Broth at 37°C to OD600 ∼0.6, and the temperature dropped to 18°C for 30 min. IPTG was 
added to a final concentration of 1 mM, and the culture was grown overnight (∼16 hr). 
Cells were harvested by centrifugation and lysed using a French pressure cell. An IMAC 
column was loaded with clarified lysate, washed with 20 mM imidazole, and eluted with 
250 mM imidazole. Protein-containing fractions were pooled, dialyzed, concentrated, and 
flash frozen. To minimize photobleaching, all expression and purification steps were 
performed in the dark. The purity of the fluorescent proteins was >90% after the nickel 
column as judged by Coommassie Brilliant Blue stained SDS-PAGE. 
Cell-based IGF1R activity assays 
IGF1R cell-based assays were based on established procedures (Liu, et al., 2012). 
HEK293 cells (ATCC) were maintained in adherent culture in DMEM:F12 supplemented 
with 5% FBS. HEK293 cells were chosen due to low background endogenous IGF1R as 
judged by Western blot and equal transfection efficiency of IGF1R wild-type and kinase-
inactive (D1205A/N) when compared with transient transfection of igf1r (−/−) mouse 
embryonic fibroblasts (a generous gift from R Baserga). HEK293 cells were plated in a 
six-well plate at 1 × 106 cells/well and transiently transfected with IGF1R expression 




Warrington, Pennsylvania) at an optimized ratio of 1 μg DNA: 3 μg PEI. Variant IGF1R 
genes were subcloned into pSSX-F, a version of pSGHV0 modified to eliminate the 
growth hormone tag and add a C-terminal Flag tag (Leahy, et al., 2000). After 18 hr, cells 
were washed three times with 2 ml Ham's F12 supplemented with 1 mg/ml BSA and 
incubated in this medium for 3 hr at 37°C to serum starve. In designated wells, 20 nM 
IGF1 was added and incubated for 30 min at 37°C. 
For cross-linking assays and assays using truncated IGF1R variants, the wells 
were washed with ice-cold phosphate buffered saline and then lysed for 30 min at 4°C in 
250 μl of RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS) supplemented with 1 mM activated Na3VO4, 1 mM PMSF, 
Benzonase nuclease (Sigma), and 10 mM iodoacetamide to prevent further disulphide-
bond formation during lysis (Cao, et al., 1992). Lysates were clarified and samples were 
separated by either denaturing reducing or non-reducing SDS-PAGE electrophoresis. 
Western blot analysis was performed using anti-IGF1Rβ (Santa Cruz Biotechnologies, 
Dallas, Texas) Western blots were developed using ECL2 (Thermo Scientific) and 
scanned using a Typhoon Imager. Bands corresponding to phosphorylated IGF1R from 
the 4G10 Western blot were quantified using ImageJ and normalized to receptor 
expression from quantified bands of the IGF1R-β Western blot for each experiment. 
For autophosphorylation analysis, the wells were washed with ice-cold phosphate 
buffered saline and lysed in supplemented RIPA buffer lacking iodoacetamide. The cell 
suspension was clarified, and total protein concentration determined using the BCA 




truncated IGF1R proteins, Western blot analysis was performed on cell lysates using anti-
IGF1Rβ or anti-IGF1R phosphotyrosine 1135 (pY1135) (Cell Signaling Technology, 
Danvers, Massachusetts) antibodies. For assays with IGF1R-fl proteins with kinase 
clusters, single cysteine substitutions, or TM mutations immunoprecipitation was 
performed. Anti-Flag-M2 (Sigma) was added at 0.5 μg/ml to lysate followed by the 
addition of 20 μl Protein G Sepharose 4 Fast Flow (GE Healthcare). Lysates were then 
incubated overnight at 4°C. Beads were then washed three times with 1 ml of RIPA 
buffer supplemented with 1 mM activated Na3VO4. Beads were eluted by the addition of 
20 μl of 5× LDS loading buffer containing 10% fresh β-mercaptoethanol. Equal amounts 
of eluted proteins were analyzed as described for the cross-linking analysis but using both 
anti-pY and anti-IGF1Rβ antibodies. 
Confocal microscopy and quantitative imaging FRET 
CHO cells were cultured in DMEM-F12 supplemented with 5% FBS and 1 mM 
L-glutamine. Cells were seeded in 35-mm dishes at a density of 4 × 104 cells per well and 
grown for 24 hr at 37°C in 5% CO2, then transiently co-transfected with plasmids 
encoding IGF1R TM-EYFP (3 μg) and IGF1R TM-mCherry (6 μg) using the Fugene HD 
transfection reagent at a mass ratio of 3:1 (Fugene:DNA) according to the manufacturer's 
protocol. 
After 24 hr, cells were washed twice with 1 ml of 30% PBS, one minute per wash. 
1 ml of chloride salt vesiculation buffer (Del Piccolo, et al., 2012) was added to each 
well, and the wells were incubated at 37°C, 5% CO2. Vesiculation buffer is composed of 




Vesiculation reached completion after about 12 hr, and the entire well supernatant was 
transferred to 4-well chambered slides (Thermo Scientific, Nunc Lab-Tek II). The wells 
were allowed to equilibrate to room temperature before imaging. 
Vesicle images were acquired using a Nikon C1 laser scanning confocal 
microscope equipped with a 60× water immersion objective. Three scans were taken for 
each vesicle: (i) a ‘donor’ scan (λexc = 488 nm, λem = 500–530 nm), (ii) an ‘acceptor’ scan 
(λexc = 543 nm, λem = 650 nm longpass), and (iii) a ‘FRET’ scan (λexc = 488 nm, λem = 
565–615 nm). The donor and FRET scans used a 488 nm argon ion laser excitation 
source, while the acceptor scan used a 543 nm He-Ne laser. The image resolution was 
512 × 512 pixels, with a pixel dwell time of 1.68 μs. The gains were set to 7. All images 
were processed using a Matlab program developed in the Hristova laboratory. The 
program finds the boundary of each vesicle, verifies that the vesicle is present in all three 
scans, and fits the intensity profile across the membrane to a Gaussian function. The 
baseline is fitted with an error function. Details for the calculations of FRET efficiency 
are provided in the study by (Chen, et al., 2010a) (Chen, et al., 2010b) We calculated the 
intrinsic FRET efficiency as: 
Intrinsic FRET = (Eapp−Eproximity)/Xa 
where Eapp is the apparent FRET efficiency observed in each vesicle, Eproximity is 
contribution of FRET from nonspecific interactions (King, et al., 2014), and Xa is a 
correction factor which accounts for varying ratios of donor and acceptor molecules 




To determine fluorescent protein concentration in the vesicles, vesicle 
fluorescence intensities were normalized to standard solutions of mCherry and EYFP 
purified from E. coli BL21 cells using the formula (Chen, et al., 2010a) (Chen, et al., 
2010b): 
E = 1 − ImDImD + ImD,corr 
where ImD is the emission intensity of the donor per unit area of the membrane in the 
presence of RET, and ImD,corr is the donor emission intensity in the absence of RET. 
Bleed-through coefficients were calculated from confocal images of standard solutions of 
purified EYFP and mCherry. Using absorption and emission spectra of purified proteins, 
we calculated the Förster radius for the EYFP-mCherry donor–acceptor pair to be 53.1 Å. 
Two photon FRET microscopy on living cells 
We employed two donor–acceptor FRET pairs for this study: mTurquoise-YFP 
and YFP-mCherry. We calculated the Förster radius for each pair to be 54.5 Å 
(mTurquoise-EYFP) and 53.1 Å (EYFP-mCherry), making them suitable for 
investigating conformational changes on the order of 30–90 Å. CHO cells were cultured 
in 35-mm collagen-coated glass bottomed dishes (MatTek Corporation, Ashland, 
Massachusetts) using phenol red-free DMEM-F12 supplemented with 5% FBS and 1 mM 
L-glutamine. Plasmids encoding the IGF1R extracellular and transmembrane regions 
fused after GGSGGS to mTurquoise (FRET donor) or EYFP (FRET acceptor) were co-




(Fugene:DNA), according to the manufacturer's protocol. Transfection proceeded for 24 
hr at 37°C, 5% CO2. 
We used the OptiMiS TruLine Spectral Scanning System (Aurora Spectral 
Technologies, Milwaukee, Wisconsin) for two-photon microscopy. A solid-state 
continuous wave laser pumped a mode-locked Ti:Sapphire laser (MaiTai DeepSee, 
Newport Corporation, Irvine, California) that generated near infrared pulses in the 
wavelength range of 800–960 nm (λexc for mTurquoise = 800 nm; λexc for eYFP = 960 
nm). The beam was focused using a 63× objective (Nikon, Japan). Fluorescence emission 
from the sample chamber was projected through a transmission grating onto a cooled 
electron-multiplying charge-coupled device. The full spectral scans of all pixels in the 
viewing field (300 × 440 pixels) were completed in about 10 s. 
Image acquisition and processing are based on the method described by Raicu et 
al. (2008). Prior to imaging, CHO cells were washed three times in 1× PBS to remove all 
traces of FBS, then serum starved in phenol red-free DMEM-F12 without FBS. After 5 hr 
of starvation, the media were changed a final time and the cells were imaged directly in 
the two-photon microscope. Individual donor and acceptor fluorescence spectra were 
collected from cells expressing either the donor- or acceptor-fused IGF1R alone. A single 
‘FRET’ scan (λexc, two photon = 800 nm) was acquired for each cell that coexpressed both 
EYFP and mTurquoise-fusion proteins. The full spectral emission profile was collected 
from 450–600 nm (1 nm resolution), and the FRET efficiency per pixel (EDapp) was 





EDqapp ≡ FD(RET)FD(λex)= =11+Q
AQDkDAkADwDwA 
where FD(RET) and FD(λex) equal the fluorescence emission of the donor in the presence and 
absence of resonance energy transfer, respectively. QA and QD are the quantum yields of 
the donor an acceptor fluorophore, and kDA and kAD are the maximum emission intensities 
of the donor in the presence of the acceptor, and the acceptor in the presence of the 
donor, respectively. The integrals of the individual emission spectra for the donor and 
acceptor are given by wD and wA. Representative pixels in each cell membrane were 
examined by eye to ensure a good fit to the FRET model. We calculated the Förster 
radius for the mTurquoise-EYFP donor–acceptor pair to be 54.5 Å using measured 













Figure 2.1. The extracellular domain of IGF1R autoinhibits IGF1R activity. 
 
Figure 2.1. (A, B) Schematic and cartoon representations of IGF1R. Numbering refers to 
human IGF1R excluding the signal sequence. Disulfide bonds are indicated by black 
diamonds. One αβ subunit is shown in outline and the other in color. (C) Cartoon of 
IGF1R full-length (IGF1R-fl) or an IGF1R fragment lacking the L1 domain (IGF1R 
ΔL1) (left). HEK293 cells expressing either IGF1R-fl (FL) or IGF1R ΔL1 (ΔL1) were 
incubated with or without IGF1. IGF1R proteins were immunoprecipitated from 
normalized cell lysates and levels of autophosphorylation or IGF1R expression detected 




Molecular weight standards indicated to the left of each panel (D). Diagram of IGF1R 
variant lacking the ECD (IGF1R TM-icd) (left). Western blots probed with anti-pY1135, 
which recognizes a phosphotyrosine on the activation loop of the IGF1R kinase domain, 
and anti-IGF1Rβ of normalized lysates from cells expressing IGF1R-fl (FL) or IGF1R 
TM-icd (TM-icd), in the presence and absence of IGF1 (right). All panels are from the 

















Figure 2.2. Conserved IR ECD dimer interaction. 
 
Figure 2.2. (A) Surface representation of the unliganded IR ECD (PDB 3LOH; (Smith, et 
al., 2010)) oriented to show the L1:Fn2'-3' interface. The hinge between CR and L2 is 
indicated by a cyan circle. Cartoons of domains shown are to the upper right of each 
structure. (B) Surface representation of ligand-bound IR ECD fragment (PDB 3W14; 
(Menting, et al., 2013)) in the same orientation as in A. The missing Fn2-3 domains are 
indicated by dashed lines. (C) Superposition of the ligand-bound IR structure (purple 
ribbon) onto the unliganded structure (orange and white ribbon) using the L2-Fn1 domain 
pairs. Insulin is displayed in light green. An arrow shows the direction of the relative 
movement of unsuperposed L1-CR domains about a hinge (cyan circle) between the CR 
and L2 domains. Complementary halves of each receptor subunit were omitted for 




Figure 2.3. The IGF1R ECD maintains TM separation 
 
Figure 2.3. (A) Cartoon of the IGF1R ECD-TM-fp variant utilized in the live cell FRET 
assay (top). Frequency distribution of FRET efficiency values per membrane pixel of 
IGF1R ECD-TM-fp in the presence (green) or absence (white) of IGF1 (bottom). Data 
were fit to a normal distribution with peak values of 0.34 ± 0.09 and 0.21 ± 0.13 in the 
presence and absence of IGF1, respectively. (B) Cartoon of the IGF1R-fl and IGF1R 
variants with flexible linkers (top). Representative western blots probed with either anti-
pY and anti-IGF1Rβ antibodies of immunopreciptated, normalized cell lysates of 
untransfected cells (U) or cells transfected with IGF1R-fl (WT) or IGF1R variants with 
an additional 4 (+4), 9 (+9), 14 (+14), or 20 (+20) glycine and serine residues per αβ 
chain (middle). Bar graph of average IGF1R phosphorylation normalized to total receptor 
concentration (±s.e.m.) from at least three separate experiments, except for +14 which 
was from 2. Results from cells incubated in the absence of IGF1 are shown in white and 




Figure 2.4. Intrinsic FRET efficiency in vesicles, corrected for proximity FRET 
and varying donor-to-acceptor ratios. 
 
Figure 2.4. Intrinsic FRET efficiencies between isolated IGF1R TM-fp (pink circles), 
IGF1R ECD-TM-fp with IGF1 (green circles) or without IGF1 (white circles), IGF1R 
ECD-ΔL1-TM-fp (blue circles), and IGF1R ECD-TM-fp H905C (yellow circles), plotted 
as a function of the total receptor, IGF1R-YFP and IGF1R-mCherry, concentration. Each 
data point represents the binned FRET efficiency measured from at least eight vesicles 
(±s.e.m. in x and y). Intrinsic FRET is the observed FRET corrected for differences in 
expression of donor and acceptor proteins and corrected for FRET resulting in random 
proximity. The remaining data were fit to a horizontal line with y intercept of 0.21 ± 0.01 
for IGF1R ECD-TM-fp without IGF1 or 0.34 ± 0.02 for with IGF1, 0.36 ± 0.02 for 






Figure 2.5. IGF1R TMs associate 
 
Figure 2.5. (A) Sequence alignment of human IGF1R and IR extracellular 
juxtamembrane and TM regions. The position of the TM is indicated above the 
alignment. Bold lettering highlights residues targeted for substitution. H905 (red) and 
P911 (blue) are colored. (B) IGF1R TM monomer and dimer structures observed in MD 
simulations are shown in ribbon (white and pink). Shown in spheres are P911 (blue) and 
H905 (red). The lipid bilayer is in light gray. (C) The intrinsic FRET efficiency for 




is IGF1R ECD-TM-fp in the presence (green) or absence (white) of ligand. Each data 
point represents the binned average of at least eight vesicles (±s.e.m. in both x and y). For 
IGF1R TM-fp, the data were fit to a two state association model with a peak value of 
0.38 ± 0.02. (D) Cartoon of IGF1R TM-icd with the positions of single-site cysteine 
mutations indicated in red (top). Anti-IGF1Rβ Western blots of lysates of HEK293 cells 
expressing either IGF1R-fl or IGF1R TM-icd fragments (WT, 898C or 905C) incubated 
















Figure 2.6. TMs associate in active IGF1R-fl 
 
(A) Cartoon of IGF1R-fl with cysteine substitutions (top). Western blots of 
immunoprecipitated normalized cell-lysates from untransfected cells (U) or cells 
transfected with IGF1R-fl (WT) or IGF1R-fl proteins with cysteine substitutions (895C, 
898C, or 905C) incubated the presence or absence of IGF1 (bottom). All panels are from 
the same blot. (B) Plot of the intrinsic FRET efficiency of IGF1R ECD-TM-fp with the 
H905C substitution (yellow) and fit to a horizontal line with a value of 0.38 ± 0.02. Each 
data point represents the binned average of at least eight vesicles (±s.e.m. in both x and 
y). For reference, the intrinsic FRET efficiencies and fits for IGF1R ECD-TM-fp with 







Figure 2.7. Model of IGF1R activation 
 
Figure 2.7. (A) Cartoon model of IR family activation. The IDs are shown as black lines 
in the ECDs, the disulfide linkages as black diamonds, phosphorylation as pink circles, 
activation loops as purple lines, ligand as green diamonds, and αCTs as cylinders. 
Surface representations and corresponding cartoon diagrams of (B) the ECD of 
unliganded-IR (PDB 3LOH; Smith et al., 2010), (C) insulin bound to the IR ECD 
fragment (PDB 3W14; Menting et al., 2013), or (D) a model of the entire IR ECD bound 
to two Insulin molecules. For each panel, one αβ subunit is colored white and the other 
orange, and Insulin green. Dashed lines outline the Fn2-3 domain tandems. The hinge 
point between F1 and Fn2-3 domains is indicated by black circles and cyan circles 




Chapter 3:  The ErbB1 and ErbB2 intracellular domains 
promote ligand-independent dimer formation 
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Introduction 
Human epidermal growth factor receptor EGFR/ErbB1 and its homolog, 
HER2/ErbB2, play important roles in both health and disease. While both are essential 
for normal growth and development, abnormal activation of either promotes the 
progression of glioblastoma, non-small cell lung cancer, and breast cancer. ErbB1 and 
ErbB2 are integral membrane proteins composed of an extracellular domain (ECD), a 
single transmembrane alpha-helix, and an intracellular domain (ICD). The ICD comprises 
a juxtamembrane region, a tyrosine kinase domain and a ~230 amino acid c-terminal tail 
of unknown structure. Several decades of research have established that ErbB1 functions 




(EGF) or several of its homologs to the ECD promotes ErbB1 dimer formation and 
stimulates tyrosine kinase activity. 
Many experiments indicate that a fraction of cell-surface ErbB1 is dimeric in the 
absence of ligand (Macdonald & Pike, 2008) (Liu, et al., 2007) (Nagy, et al., 2010) 
(Saffarian, et al., 2007) (Chung, et al., 2010), which suggests free ErbB1 exists in 
equilibrium between monomers and dimers. Despite considerable progress, the nature 
and strength of ligand-independent ErbB1 dimers remains elusive, as estimates of the 
fraction of ligand-independent dimers range from 14-75% (Table 3.1).  The high variance 
may be explained in part by the variety of experimental techniques, cellular contexts, and 
reported ErbB1 expression levels present in different studies (Table 3.1). Further 
uncertainty stems from an incomplete understanding of the nature and signaling 
competence of the unliganded ErbB1 dimer. In particular, the relative contributions of 
each domain in mediating ligand-independent dimer formation remain unclear. 
A complete model for the mechanism of ErbB1 activation requires understanding 
how the receptor maintains itself in an inactive state when not bound to ligand. On this 
point, the principal functions of each domain are known to varying degrees. In the 
absence of ligand, the ECD adopts a tethered conformation that may play a role in 
receptor autoinhibition (Cho & Leahy, 2002) (Ferguson, et al., 2003) (Bouyain, et al., 
2005) (Endres, et al., 2013). Binding of EGF to the ECD promotes an extended 
conformation, which exposes an extended β-hairpin (termed the ‘dimerization arm’) that 
mediates the active receptor dimer. Disrupting the intradomain tether fails to activate the 




induced inhibits receptor activation (Ogiso et al. 2002, Garrett et al. 2002). The precise 
mechanism by which the ECD achieves autoinhibition thus remains an area of intense 
research (Bessman, et al., 2014) (Lee, et al., 2015). Comparatively little is known about 
the inactive state of the TM domain or ICD, though a mechanism by which the TM may 
function in the inactive state has been proposed (Endres, et al., 2013) (Arkhipov, et al., 
2013) (Ben Tal et al., 2002). 
What then are the determinants of ligand-independent association, what are the 
barriers to the formation of the active state, and how does ligand binding overcome them? 
To address these issues, we present quantitative Forster resonance energy transfer 
(FRET) measurements of ErbB1 and ErbB2 interactions in vesicles derived from plasma 
membranes. We show that the transmembrane (TM) domains of EGFR and ErbB2 have 
an intrinsic propensity to form homo- and hetero-dimers. The ECDs disrupt intrinsic TM 
interactions, while the intracellular domains promote dimer formation in the absence of 
ligand. Mutations in the asymmetric dimer interface important for kinase activation do 
not affect the formation of ligand-independent dimers. ErbB receptors form dimers as a 
function of membrane surface concentration, and the two-dimensional dissociation 
constant falls within the known range of physiological expression. These results implicate 
the ICD as a driver of dimer formation in the absence of ligand and suggest that inactive, 
ligand-independent ErbB1 dimers may utilize an interface that is distinct from the 





Quantitative Imaging FRET Microscopy 
We generated variants of ErbB1 and ErbB2 with either a FRET donor (EYFP) or 
acceptor (mCherry) fused to the C-terminus (Fig. 3.1A). Each ErbB-FP (FP: fluorescent 
protein) fusion protein was activated in a ligand-dependent manner in CHO cells (Fig. 
3.1B). We then employed quantitative imaging FRET (QI-FRET) microscopy, a method 
that permits measurements of protein-protein interactions in plasma-membrane vesicles 
formed by exposing cells to high salt concentrations. The details of the method have been 
described in detail elsewhere (Li, et al., 2008) (Chen, et al., 2010a) (Chen, et al., 2010b). 
Briefly, receptor variants fused separately to EYFP or mCherry were transiently co-
transfected into CHO cells, resulting in a wide range of expression in a single experiment. 
The dimerization-impaired A206K variant of EYFP was used, which reduces the solution 
EYFP dimerization constant from 111 µM to 74 mM (Zacharias, et al., 2002). The FRET 
efficiency was measured in CHO cell plasma membrane-derived vesicles, referred to 
hereafter simply as “vesicles” (Fig. 3.6). EGF-dependent receptor activity was preserved 
in vesicles generated from A431 cells, which express ErbB1 endogenously (Fig 3.6B). 
Each experiment yields the measured FRET efficiency as a function of concentration 
(Fig. 3.6C). We then calculate the ‘corrected FRET’, which accounts for contributions 
due to interactions resulting from random proximity as well as different ratios of donor 




The efficiency of resonance energy transfer between fluorescent donor and 
acceptor molecules depends on both the relative orientation and distance separation 
between the two respective transition dipole moments (Lakowicz, 2006). To mitigate any 
effects of orientation of the FPs on FRET measurements, we included a flexible 8-amino 
acid linker sequence between each receptor variant and its FP fusion partner. We assume 
any changes in FRET mostly reflect changes in distance separation. For the case of the 
receptor-receptor interactions studied here, we interpreted concentration-dependent FRET 
changes as resulting from a change in oligomeric state. Conversely, FRET values that did 
not change with 2D-concentration were assumed to represent a single oligomeric state. 
Where appropriate, we fit the data to a monomer-dimer equilibrium model which 
includes to parameters: 1) the ‘intrinsic FRET’, Ẽ, which equals the FRET efficiency 
within a dimer and 2) the two-dimensional (2D) dissociation constant, K, in units of 
molecules/μm2 (cite pertinent Hristova FRET papers). In cases where the association was 
too strong to determine, we assumed the intrinsic FRET value (Ẽ) was to equal the mean 
of the distribution over all concentrations. 
The ErbB1 and ErbB2 TM domains form homo- and hetero-dimers in membrane-derived 
vesicles 
The single TM domains of ErbB1 and ErbB2 are known to associate in bacterial 
membranes (Mendrola, et al., 2002). To investigate the strength of these interactions, we 
measured the FRET efficiency as a function of 2D-membrane concentration 
(molecules/μm2) for three interaction pairs in CHO vesicles: (i) the homodimer of ErbB1-




and ErbB2-TM-fp. These receptor variants consisted of the transmembrane domains 
linked to a fluorescent protein (Fig. 3.1; pink circles in Fig. 3A-C). We could not 
determine the dimer dissociation constants for each of the three pairwise interactions, 
which likely fall too far below the sensitivity limit of the experiment (about 200 
molecules/µm2). The FRET efficiency changed little with concentration, and the mean for 
each population was ~0.35. Within the membrane environment of the vesicle, the isolated 
TM domains therefore showed a strong propensity to form dimers in the absence of the 
extracellular and intracellular domains. 
ErbB extracellular domains inhibit intrinsic transmembrane (TM) domain interactions 
Since the ErbB ECDs are known to function in an autoinhibitory manner 
(McManus, et al., 1997) (Boerner, et al., 2000) (Ferguson, et al., 2003) (Bouyain, et al., 
2005) (Cho & Leahy, 2002) (Endres, et al., 2013), we investigated the effect of the ECDs 
on the TM domain association. In the absence of ligand, the FRET efficiency decreased 
for receptor variants that include both the ECD and TM domains (Fig. 3.2) relative to the 
FRET measured for the TM domains alone (Fig. 3.2A-C, compare pink and grey circles). 
ErbB1-ECDTM-fp alone showed low (<0.1) FRET efficiency at concentrations below 
1000 molecules per μm2, with FRET efficiency increasing modestly to ~0.2 at receptor 
concentration levels of 3000 per μm2 (Fig. 2A). In a similar manner, the FRET efficiency 
for ErbB2-ECDTM-fp stayed below 0.2 over all receptor concentrations measured (Fig. 
3.2C). We were unable to reliably fit the data for homo-interactions of either ErbB1 or 
ErbB2 to a monomer-dimer equilibrium. In contrast to the homodimer cases, unliganded 




receptor concentration in the absence of ligand (Fig. 3.2C). The best fit value for the 
dimer dissociation constant was 704 molecules/μm2. 
We then measured the FRET efficiency as a function of receptor concentration for 
these variants (ECD-TM) in the presence and absence of EGF (Fig. 3.2A and Fig. 3.2C). 
Binding to EGF led to an increase in FRET efficiency for homodimers of ErbB1-
ECDTM-fp (Fig. 3.2A, Ẽ = 0.39) and heterodimers of ErbB1-ECDTM-fp and ErbB2-
ECDTM-fp (Fig 3.2C, Ẽ = 0.39) for all observed receptor concentrations. In agreement 
with similar experiments using luciferase-fragment complementation (Macdonald-
Obermann, et al., 2012) these data indicate that: i) EGF binding to the ECD of ErbB1-
ECDTM-fp promotes dimer formation, and ii) the TM domains come into close 
proximity within this dimer. For all ligand-independent interactions, the 95% confidence 
intervals for both model parameters were large (K and Ẽ; 95% CI ≥ mean). It is therefore 
difficult to distinguish between a very weak dimer with high intrinsic FRET and a 
stronger dimer with low intrinsic FRET, though in either case the ECD effectively 
separates the TM domains. 
To examine the FRET efficiency for a constitutively dimeric control protein, we 
replaced the ECD of ErbB1-ECDTM-fp with the mouse immunoglobulin Fc-region. 
Since the mouse IgG-Fc is constitutively dimeric, we reasoned that fusing it to the N-
terminus of the ErbB1 TM region would result in a strong dimer with high FRET 
(Bessman, et al., 2014). Indeed, the measured FRET efficiency for Fc-ErbB1-TM-fp was 
high (Ẽ = 0.43) and showed no change with concentration, consistent with the expected 




Importantly, the data overlay closely with the measured FRET for ErbB1-ECDTM-fp in 
the presence of saturating EGF, suggesting that the ErbB1-ECDTM-fp population in this 
condition is mostly dimeric. 
The ErbB intracellular domains promote dimer formation in the absence of ligand 
Our results indicate that ErbB TM domains associate on their own, but that ECDs 
counteract this effect. We then examined the relative contribution of the intracellular 
domain (ICD) to ligand-independent dimer formation. Preliminary experiments using 
full-length variants of ErbB1 and ErbB2 with fluorescent proteins fused to the C-terminus 
were inconclusive. The total membrane expression of these variants was below 200 
molecules/μm2, though expression and activity were detectable by western blot (data not 
shown). Removal of 107 and 25 amino acids from the C-termini of ErbB1 and ErbB2, 
respectively, resulted in variants that increased membrane surface expression by about 5-
fold. These truncations do not impair ligand-dependent activity (Fig. 3.1B). 
 For all pairwise near full length ErbB-fp interactions measured, we observed that 
the ICDs promote dimer formation in the absence of ligand (Fig. 3.3). We detected a 
concentration-dependent increase formation in FRET efficiency for homodimers of 
ErbB1-Δ107-fp, with a best fit value for the 2D dimer dissociation constant (Kd) of 146 
molecules/μm2 (Table S1). Homodimers ErbB2-Δ25-fp and heterodimers of ErbB1-
Δ107-fp and ErbB2-Δ25-fp interacted strongly: the FRET efficiency was high (~0.4) and 
remained fairly constant with increasing concentration, consistent with the behavior for a 
constitutive dimer. Addition of EGF led to an increase in FRET for the homodimer of 




range, and the intrinsic FRET (Ẽ) was not statistically different between ligand-
independent and EGF-bound ErbB dimers. Ligand binding thus increases the 
oligomerization propensity of near full length ErbB-fp variants, while the average 
distance between the fluorescent dipoles for ligand-independent and EGF-bound dimers 
(or oligomers) is similar. 
EGF-independent ErbB1 phosphorylation increases with increasing receptor surface 
density 
Gene amplification of ErbB1 and ErbB2 is associated with the genesis and 
progression of subsets of glioblastoma and breast cancers, respectively (Ekstrand et al., 
1991) (Slamon et al., 1989). Increased ErbB1 cell surface expression results in ligand-
independent receptor phosphorylation at tyrosine-1068 (Endres, et al., 2013) (Valley et 
al., 2015), which implies that some fraction of unliganded dimers samples the active 
state. To further examine the relationship between dimerization and activation, we 
generated a panel of CHO cell lines stably expressing full length ErbB1 fused to EYFP at 
the C-terminus (ErbB1-EYFP). The apparent ErbB1-EYFP surface concentration was 
measured in vesicles derived from each cell line and ranged from <100-300 receptors per 
μm2 on average (Fig. 3.4A and Fig. 3.8). Cells treated with and without EGF were 
analyzed by western blot for ErbB1 and pTyr (Fig. 3.4A-C). In the absence of ligand, 
ErbB1 phosphorylation was not detectable at concentration levels below 100 
molecules/μm2. Between 100 and 300 molecules/μm2, ligand-independent 
phosphorylation increased in a linear fashion. Stimulation with EGF results in a steady 




Interestingly, the ErbB1-EYFP expression range over which EGF-independent 
phosphorylation begins to rise (100-300 molecules/μm2) agrees closely with the best fit 
value for the 2D-dissociation constant for ErbB1 (146 molecules/μm2). Together, these 
data suggest that surface density-dependent dimerization might underlie ligand-
independent activation. 
We also examined the influence of ErbB1 overexpression on two downstream 
signaling pathways: STAT and MAPK/Erk (Fig. 4A). Increased expression of ErbB1 had 
no measurable effect on Erk1/2 phosphorylation in the absence and presence of EGF, nor 
did it alter or Erk1/2 expression. The total STAT1 expression levels and the increased 
modestly (about 2 fold) with increasing ErbB1 expression. Interestingly, the level of 
EGF-dependent pSTAT1 was enhanced in ErbB1-YFP overexpressing cells (Fig. 3.4, 
Fig. 3.9). We did not observe background phosphorylation of either STAT1 or Erk1/2 in 
any of the CHO ErbB1-YFP cell lines, regardless of ErbB1 expression level. 
Disrupting the asymmetric dimer interface does not impair ligand-independent dimer 
formation 
A key feature of activated ErbB1 dimers is the formation of an asymmetric 
interface between kinase domains within a dimer, termed the “asymmetric kinase dimer”. 
Two single-residue substitutions at this interface, one located in the kinase N-lobe 
(I682Q), the other in the C-lobe (V924R), each themselves abolish ErbB1 activity. Co-
expression of ErbB1-I682Q with ErbB1-V924R restores ligand-dependent activity 




phosphorylation, we wondered if the asymmetric kinase interface might also mediate the 
formation of unliganded ErbB1 dimers. 
Despite evidence that unliganded dimers possess some intrinsic activity (Fig. 3.4) 
(Valley et al., 2015) (Endres, et al., 2013), we observed that disrupting the asymmetric 
dimer interface does not affect formation of ligand-independent ErbB1 dimers (Fig. 3.5). 
We introduced the I682Q and V924R mutations into the ErbB1-Δ107-fp variant, then 
measured the dimerization propensity of each with our FRET assay in vesicles. Neither 
variant had a strong effect on the propensity for ErbB1 to form ligand-independent 
dimers. In the absence of EGF, the dimerization coefficients for the I682Q and V924R 
variants were 209 and 178 molecules/μm2 (Fig. 3.5B-C), which do not differ significantly 
from the value determined for the wildtype receptor. 
The kinase-activating L834R mutation promotes ligand-independent ErbB1 self-
association 
 Two ErbB1 variants associated with lung cancer (L834R and Δ722–726) are 
located within the ErbB1 kinase domain. Both induce ligand-independent receptor 
activity, in part because they enhance the propensity for ErbB1 to form active dimers 
(Zhang, et al., 2007) (Shan et al., 2012) (Valley et al., 2015). To investigate the effect of 
a kinase-activating mutation on the strength of ErbB1 self-interactions, we introduced the 
L834R mutation to ErbB1-Δ107-fp and measured its FRET efficiency in membranes. 
ErbB1L834R-Δ107-fp showed high FRET over all concentration ranges measured, 
indicating that this variant forms strong dimers (Fig. 3.3A, purple circles). Furthermore, 




EGF, which suggests that the L834R variant favors the formation of the asymmetric 
kinase and the active state. 
Discussion 
While many previous studies have documented the occurrence of preformed 
ErbB1 dimers, none to our knowledge have determined the strength of the interaction. 
Several research groups have estimated of the strength of ligand-independent dimer by 
determining the expression level of the cell line under study (Table 3.1). While 
informative, these measurements are limited in one important respect: each is derived 
from a population of cells. Since the distribution of ErbB1 expression may vary 10-100 
fold even within a monoclonal cell line population, any estimates of the fraction of 
dimers will necessarily represent the population average. Furthermore, these studies 
measured expression levels in numbers of molecules per cell, which makes limiting 
assumptions about the complex topology of the membrane. 
To overcome these limitations, we used QI-FRET, a method that enables direct 
observation of dimer formation between ErbB-fp variants embedded in membrane 
vesicles. For each individual vesicle in a population, we experimentally determined both 
the FRET efficiency and the 2D membrane concentration. QI-FRET also accounts for the 
effect of stochastic interactions that result from increased concentration in the 2D-
membrane environment (King, et al., 2016), which provides for clear identification of 
bona fide protein interactions. This allowed us to assess the contributions of each domain 




ErbB-fp variants composed of the TM domains alone form strong dimers in 
membrane vesicles. This appears to be a feature of all human receptor tyrosine kinase 
TM domains (Finger, et al., 2009). In contrast, variants composed of both the ECD and 
TM domains exhibit reduced association (Fig. 3.2). The ECD thus acts as a barrier to TM 
region association.  Interestingly, neither the unliganded ErbB1 ECD nor the TM 
domains form dimers in solution (Lemmon, et al., 1997) (Stanley & Fleming, 2005). 
Restriction to the plasma membrane must therefore promote TM dimerization, likely due 
to increased local concentrations and a reduction in translational and rotational degrees of 
freedom in going from a 3D solution into the 2D membrane (Lin, et al., 2014). In 
contrast, an autoinhibitory role for the ganglioside GM3 on ErbB1 activation has been 
observed by others (Coskun, et al., 2011). The plasma membrane-derived vesicles used in 
our experiments do contain a fraction of GM3 (1-2 mole %), though we did not examine 
the effect of GM3 on ErbB1 dimer formation in our experiments (Sarabipour, et al., 
2015). It is clear that the role of the membrane in regulating ErbB oligomer formation 
warrants further investigation. 
Our results identify the ICD as a critical mediator of ligand-independent dimers 
(Fig. 3.3), consistent with implications from previous experiments. Deleting the ErbB1 
ICD leads to a decrease in ligand-independent receptor crosslinking in cells (Yu, et al., 
2002) , as well as a loss of negative cooperativity in binding to EGF (Macdonald & Pike, 
2008). Furthermore, our experiments concur qualitatively with single molecule 
observations of ErbB1 in cell membranes. Measurement of average ErbB1 dimer 




the intracellular domain (tD = 4.5 ± 0.1 s) reduced the dimer lifetime relative to wildtype 
(tD = 13.0 ± 1.2 s) (Chung, et al., 2010). 
Our interpretation of the 2D-dissociation constants is necessarily limited, since we 
lack a complete understanding of the ErbB1 surface concentration levels under various 
physiological conditions. Expression levels are typically reported as the average number 
of receptor molecules/cell, whereas our measurements are in units of molecules/μm2. 
Caution should be taken when converting between these two units of measure, since 
doing so requires making simplifying assumptions about the geometry of the plasma 
membrane. We can nevertheless estimate that the best fit 2D-dissociation constant we 
measured for ligand-independent ErbB1 dimers (Table S1) corresponds to ~140,000 
receptors/cell, assuming a radius of 9 μm and spherical geometry for a CHO cell (Fig. 
3.8). This figure falls well within the range of ligand-independent ErbB1 dimeric 
fractions reported in the literature (Table 3.1). A recent study reported the surface 
expression levels in A431 cells (646 molecules/μm2), which again places the observed KD 
for preformed ErbB1 dimers in the range of intermediate expression (Zhang et al, 2015). 
Thus under conditions of low expression (~10,000 receptors/cell) we estimate that the 
receptor is only ~10% dimeric, whereas oligomers dominate at high expression levels 
(~70% dimer fraction at 500,000 receptors/cell). 
In ErbB1-YFP overexpressing cells, the total amplitude of EGF-independent 
ErbB1 phosphorylation is roughly equal to the amplitude of EGF-dependent 
phosphorylation in low-expressing cells (Fig. 3.4, compare lanes 1-2 to lanes 11-12). 




phosphorylation of either Erk1/2 or STAT1, although STAT1 expression does increase 
modestly (but not Erk1/2). However, any interpretation of protein expression levels 
measured in our western blot experiments should be taken with caution, due the >10-fold 
variation in expression levels within each stable cell line (Fig. 3.4A). Furthermore, 
regulation of ErbB1 downstream signaling involves a complex network of feedback and 
feedforward loops (Avraham & Yarden, 2011), and such mechanisms will likely 
influence state of ligand-independent ErbB1, STAT, and Erk phosphorylation. Indeed, 
ErbB1 undergoes rapid phosphotyosine (p-Tyr) turnover, indicating that phosphatases 
exert continual control over phosphorylation levels (Kleiman, 2011). Furthermore, pre-
treatment of ErbB1-expressing cells with orthovanadate, a pan-phosphotyrosine 
phosphatase inhibitor, results in enhanced EGF-dependent ErbB1 activation (Lahusen, et 
al., 2007) (Reddy, et al., 2016). The total level of ErbB1 phosphorylation will therefore 
depend on the two competing ErbB-kinase and phosphatase activities. 
How are ligand-independent dimers kept in a low-activity state? 
The different regions of ErbB receptors (ECD, TM and ICD) function together to 
regulate dimer formation.  The ECD plays a dual role, inhibiting dimerization in the 
absence of ligand and facilitating dimerization when ligand is bound.  On the other hand, 
both the TM and the ICD appear to promote dimer formation (Figs 3.2, 3.3).  Near full 
length ErbB1-fp can form ligand-independent dimers even if the asymmetric interface is 
disrupted by mutations (Fig. 3.5B-C). At the same time, the V924R and I682Q variants 
do not lead to ligand-independent activity (Fig. 3.5A), which suggests that some other 




the asymmetric kinase dimer when bound to EGF, though the kinase domain does appear 
make symmetric contacts under these conditions (Mi, et al., 2011). The inactive form of 
the kinase domain has also been observed to make symmetric contacts within a crystal. In 
any case, the ligand-independent and ligand-dependent ErbB dimers are indistinguishable 
in our FRET experiments (Fig. 3.3), though whether or not this reflects a true similarity 
in the kinase domain configuration between the two types of dimers is unclear. Our 
choice of large (27kDa) genetically-encoded FPs (EYFP and mCherry) necessarily 
restricted the placement of fluorescent probes to either the C-terminal ends of receptor 
variants, thereby limiting our capacity to interrogate conformational movements at 
precise locations within the ICD. Future experiments will be needed to determine the 
manner in which the ICD participates in non-asymmetric dimer contacts. 
The ECD also plays a crucial role in ErbB1 autoinhibition, though the mechanism 
of action remains obscure. Our results show that while the ECDs may reduce the 
interaction between the TM domains, they do not preclude dimer formation altogether 
(Fig. 3.2). Our experiments cannot address the precise structural nature of the unliganded 
ECDTM homodimers, since the data did not fit well to a monomer-dimer equilibrium.  
The ErbB1-ECDTM variants conforms to one of two possible models: either this variant 
forms 1) weak ligand-independent dimers that exhibit a similar degree of TM separation 
as the EGF-bound form, (K>3000 molecules/µm2, Ẽ ≈ 0.4) or 2) strong dimers that 
exhibit a greater degree of TM separation than the ligand-bound form (K<500 
molecules/μm2, Ẽ ≈ 0.4). Of the known structures of the ErbB1 ECD, the tethered 




The fact that we still observe receptor self-association in the ECDTM variants suggests 
that some fraction of unliganded receptors can sample the extended conformation. In that 
case, the relative probabilities of each state (tethered vs. extended) would likely 
determine how often the TM domains are able to interact. Of course, since the ensemble 
nature of our FRET assay reports on the average conformation within a population of 
receptors, we cannot rule out that the ECDs might adopt some other conformation that 
holds the TM domains apart in space. Consistent with this idea, a chimeric receptor 
composed of the insulin receptor (IR) ECD and the ErbB1 TM domain and ICD becomes 
activated in response to insulin binding (Reidel, et al., 1986), implying that ErbB1 and 
insulin receptor may share a common mechanism. The insulin/insulin-like growth factor 
receptor (IR/IGF1R) family involves TM domain spatial separation in the inactive state 
(McKern et al., 2006) (Kavran, et al., 2014). 
A different mode of regulation within ligand-independent dimers been proposed 
by others, one in which kinase activity appears coupled to slight conformational changes 
within dimerized TM domains (Maruyama, 2015) (Endres, et al., 2013) (Arkhipov, et al., 
2013). Changes to the TM dimer conformation may include TM domain rotation, or 
conformational switching between two GxxxG-like motifs located in the N- and C-
terminal regions of the TM domain. Neither model need exclude the other: both the 
separation of the TM domains (implied by our experiments) and the conformational 
switching between the GxxxG-like motifs (proposed by others) might each represent 
discrete steps along the path from inactive monomer to active dimer. Finally, the kinase-




(Pines, et al., 2010) (Kovacs, et al., 2015). A full understanding of the relative 
contributions of these proposed modes of regulation will require further investigation of 
intact receptors in the membrane environment. 
 
Materials and Methods 
Plasmid Construction 
The coding sequences for ErbB1, ErbB2, EYFP and mCherry were amplified 
using the polymerase chain reaction and cloned into pCDNA3.1(+) (Life Technologies). 
The sequence for EYFP was modified using site directed mutagenesis to generate the 
EYFP A206K variant. 
Cell culture and transfection 
Chinese hamster ovary (CHO) cells and A431 cells were maintained in 
Dulbecco’s modified Eagle Medium (DMEM F12) supplemented with 2 mM glutamine, 
5% FBS and grown at 37 °C, 5% CO2. For imaging experiments, CHO cells were seeded 
in 35 mm dishes at a density of 2 x 104 cells per well, then grown for 24 hours prior to 
transfection. We used the Lipofectamine 3000 transfection reagent (Life Technologies) 
according to the manufacturer’s protocol. 
Vesiculation, Image Acquisition and Analysis 
All vesiculation procedures were performed as described (Kavran, et al., 2014). 




of 100 nM and incubated for at least 1 hour prior to imaging. Vesicle images were 
acquired using a Nikon C1 laser scanning confocal microscope at 60X magnification 
(water immersion objective). For each vesicle, three scans were recorded: a ‘donor’ scan 
(λexc = 488 nm, λem = 500-530 nm), an ‘acceptor’ scan (λexc = 543 nm, λem = 650 nm 
longpass), and a ‘FRET’ scan (λexc = 488 nm, λem = 565-615 nm). Argon (488 nm) and 
He-Ne lasers were used as excitation sources. The image pixel dimensions were 512 x 
512, and the pixel dwell time was 1.68 μs, and the gains were set to 8. The Förster radius 
for the EYFP-mCherry pair was calculated to be 53.1 Å. All images were processed using 
a MATLAB program written in the Hristova laboratory which calculates the FRET 
efficiency for each vesicle. A detailed description of the analysis is found elsewhere 
(Chen, et al., 2010a) (Chen, et al., 2010b). Absolute protein concentration in the 
membrane was calculated by comparing the fluorescence intensity in vesicles with the 
intensities measured from a dilution series of fluorescent protein standards (EYFP and 
mCherry). Bleed-through coefficients were calculated for each experiment (typically ~0.3 
and ~0.2 for EYFP and mCherry, respectively). Where appropriate, the processed data 











where Xd is the fraction of dimers, Kd is the dissociation constant, and Xtot is the total 
concentration of receptor: 
 
𝑋tot = 𝑋monomer + 2(𝑋dimer). 
 
EGF Stimulation of ErbB proteins in CHO cells 
EGF was expressed in E. coli and purified as described (Qiu et al, 2009). CHO cells were 
grown to 90% confluency, then transfected and grown for 14 hours, then serum starved 
for 7 hours at 37 °C in Ham’s F12 supplemented with 1 mg/mL BSA. The cells were 
incubated in starvation media in the presence or absence of 100 nM EGF (5 minutes, 37 
°C). The medium was aspirated, the cells were washed twice with cold PBS (1X, plus 1 
mM Na3VO4), then lysed for 15-20 minutes at room temperature in RIPA buffer (150 
mM NaCl, 50 mM Tris pH 8, 1% NP40, 0.5% w/v sodium deoxycholate, 0.1% sodium 
dodecyl sulfate, 1 mM Na3VO4). The lysates were clarified by centrifugation and the total 
protein concentration of the supernatants was determined by BCA assay (Pierce, Life 
Technologies). Lysate protein concentrations were normalized, and the samples were 
analyzed by SDS-PAGE and western blot to detect phosphotyrosine (4G10, Millipore), 
ErbB1 (D38B1) ErbB1 pY1068, ErbB2 (29D8), or ErbB2-pY1221/1222 (all ErbB 





Figure 3.1 ErbB1 and ErbB2 tagged with fluorescent proteins are active in CHO 
 
 
Figure 3.1. ErbB1 and ErbB2 tagged with fluorescent proteins are active in CHO 
cells (A) Schematic representation of fluorescent protein (fp)-tagged variants of ErbB1 
and ErbB2. Abbreviations: ecd, extracellular domain; tm, transmembrane domain; icd, 
intracellular domain; jm, juxtamembrane; fp, fluorescent protein. Residue numbers are 
indicated above the full length proteins. The numbering convention is for the mature 
proteins and does not include the signal sequence for ErbB1 or ErbB2. (B) Western blots 
of CHO cell lysates with or without EGF stimulation, expressing either ErbB1-Δ107-
YFP, ErbB2-Δ25-YFP, or both. Primary antibodies are indicated next to each image. 







Figure 3.2. The ECDs impede intrinsic TM interactions, and ligand binding 
releases the constraint 
 
Figure 3.2. Corrected FRET efficiency as a function of total receptor membrane 
concentration for ErbB-TM-fp and ErbB-ECDTM variants. (A) ErbB1 homo-
interactions, (B) ErbB2 homo-interactions and (C) ErbB1 and ErbB2 hetero-interactions. 
In each plot, variants comprising the TM domain alone are shown in pink, while variants 
comprising the ECD + TM domains are shown in grey (no ligand) and green (100 nM 
EGF). Data in the absence of ligand were fit to a monomer-dimer equilibrium. Data in the 
presence of ligand were fit to a horizontal line. Error bars represent the standard error of 








Figure 3.3. The intracellular domain promotes ligand-independent 





Figure 3.3. Corrected FRET efficiency as a function of total receptor membrane 
concentration for near full length ErbB variants. (A) ErbB1-Δ107-fp in the absence (grey 
circles) or presence 100 nM EGF (green circles). The L834R variant is shown in purple. 
The data in the absence of ligand were fit to a monomer-dimer equilibrium association 
model (black line). The data in the presence of ligand (green line) and for the L834R 
variant (purple line) were fit to a horizontal line. (B) ErbB2-Δ25-fp in the absence of 
EGF (grey circles), fit to a horizontal line. (C) ErbB1-Δ107-mCherry and ErbB2-Δ25-
EYFP in the absence (grey circles) or presence of 100 nM EGF (green circles), both fit to 
a horizontal line. Error bars represent the standard error of the mean in the y-direction, 












Figure 3.4. (A) Analysis of cell surface expression and ErbB1 pathway activation. Seven 
CHO cells stably expressing ErbB1-EYFP were treated with vesiculation buffer, and the 
EYFP fluorescence was measured in a confocal microscope. Each grey dot represents a 
measurement from a single vesicle. The red line represents the population mean. In 
parallel, cell lines (A-G) were cultured and treated with and without EGF, then analyzed 
by western blot to detect expression and phosphorylation of three proteins: ErbB1, 
STAT1, and Erk1/2. Cells were also blotted for actin as a loading control. Blots represent 
at least two independent experiments. (B) Quantification of ErbB1 phosphorylation as a 
function of expression level in the presence (green dots) and absence (grey dots) of EGF; 




(C) Phosphorylation was normalized for ErbB1 expression level and grouped by cell line, 















Figure 3.5. Disrupting the asymmetric dimer does not impair ligand-
independent dimerization 
 
Figure 3.5. (A) Western blot analysis of ErbB1-Δ107-fp variants bearing mutations at the 
asymmetric dimer interface. Cartoons of each variant are shown above each blot. The 




cells transiently expression the indicated variants were treated with or without EGF. 
Antibodies recognizing phosphotyrosine (4G10) and ErbB1 are indicated at the left. (B-
C) QI-FRET experiments for the I682Q and V924R variants in (B) and (C), respectively. 
Data collected in the absence (pink, light blue) and presence (red, blue) of 100 nM EGF 
for the I682Q and V924R variants, respectively. The fit for wildtype ErbB1-Δ107-fp is 































Figure 3.6. Quantitative Imaging FRET microscopy for studying ErbB 
proteins 
 
Figure 3.6. (A) Confocal image of a plasma membrane-derived vesicle produced from 
CHO cells expressing ErbB1-ECDTM-EYFP. Scale bar indicates 10 μm. Fluorescence 
intensity (arbitrary scale) indicated by the shaded bar underneath the image (black = low 
fluorescence, white = high). (B) A431-derived vesicles were incubated for 10 minutes 
with either ATP alone (lane 1) or ATP and 100 nM EGF (lane 2). Samples were 
separated by SDS-PAGE and analyzed by western blot to detect anti-phosphotyrosine 
(pTyr) and EGFR (cytoplasmic domain). Location of molecular weight standards 
indicated at the left of each blot. (C) Example of confocal image analysis. Left: Three 




(B), and an ‘acceptor’ scan (see Materials and Methods). The shaded bar beneath each 
image denotes the relative fluorescence intensity (black = low fluorescence, white= high). 
Right: Integrated fluorescence intensity as a function of pixel number, counted from the 
center. Each plot shows the measured fluorescence intensity (black line), a Gaussian fit to 
the fluorescence intensity (turquoise line), and the difference between measured 

















Figure 3.7. Enforced dimerization of the TM domains activates ErbB1 
 
Figure 3.7. (A) Schematic of fp-tagged proteins. ErbB1-ECDTM-fp and ErbB1-Δ107-fp 
(identical to those shown in Figure 1A) are shown here for comparison with FcECD-
ErbB1TMICD-Δ107-fp and FcECD-ErbB1TM-fp. (B) Western blot analysis of lysates from 
CHO cells transiently expressing ErbB1-Δ107-fp and FcECD-ErbB1TMICD-Δ107-fp. (C) 




100 nM EGF. (D) FRET plot for FcECD-B1TM-fp (red) and ErbB1-ECDTM-fp in the 






























Figure 3.9. Effects of ErbB1 surface density on STAT1 expression and 
signaling 
 
Figure 3.9. Quantification of STAT1 phosphorylation and expression as a function of ErbB1 
expression.  Immunoblots from Fig. 3.4 were quantified in ImageJ and plotted in panels A and B.  
(A) Each dot represents the average immunoblot band intensity derived from a single population of 
cell line. (B) STAT1 phosphorylation was divided by STAT expression and plotted on the y-axis.  
Data from cells treated with EGF are labeled in green, data from cells treated with no ligands are 



























Chapter 4.  Binding of the EGF-like ligands Epigen (EPG) 
and Epiregulin (EPR) to ErbB1 induces partial 
receptor dimerization 
Note to reader:  This work is unpublished as of the time of submission. 
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Abstract 
The ErbB family of receptor tyrosine kinases play important roles in human 
health and disease.  ErbBs act as regulators of a diverse set of signaling pathways within 
the cell, and mis-activation of the receptors can result in the progression of diseases, such 
as cancer.   Eleven different ligands are known to bind to this family of receptors.  The 
precise biological roles of each still remain largely unexplored, though many are thought 
to function as important regulators of epithelial tissue growth and development.  Using 
quantitative FRET microscopy, we examined the ability of three ErbB ligands (EGF, 
epigen (EPG) and epiregulin (EPR)) to induce receptor dimerization in the membrane.  
EGF promotes strong ErbB1 dimer formation, whereas EPG and EPR promote partial 




different ligands induce dimerization of ErbB1, and may help explain the unique 
signaling properties of these three ligands. 
Introduction 
 Members of the epidermal growth factor (EGFR, or ErbB) family of receptor 
tyrosine kinases becomes activated upon binding to soluble growth factor ligands.  
Ligand binding to the EGFR extracellular domain (ECD) promotes the formation of 
activated ErbB1 dimers, which stimulates the tyrosine kinase activity within the 
receptor’s intracellular domain (ICD).  Seven growth factors are known to bind to ErbB1 
in humans, and the biological functions of each ligand are known to varying degrees of 
certainty (Schneider & Wolf, 2009).  Much of our knowledge of the ligands’ functions 
derives from genetic experiments performed in mice.  Deletion of individual ligands 
results in a variety of skin-related phenotypes, whereas overexpression can cause cell 
hyper-proliferation and is associated with tumorigenesis (Schneider & Wolf, 2009) 
(Schneider & Yarden, 2014). 
 ErbB receptors are composed of an extracellular ligand binding domain (ECD), a 
single transmembrane (TM) alpha helix, and an intracellular domain (ICD) which houses 
a tyrosine kinase.  Upon activation, the kinase domains phosphorylate tyrosines located 
within the C-terminal end of the ICD, as well as intracellular substrates.  With the 
exception of ErbB2, which has no known ligand, ErbB ECDs can adopt one of two 
conformations: a ‘tethered’ conformation and an ‘extended’ conformation (see Chapter 1, 




while the extended conformation is compatible with ligand-induced, active receptor 
dimers.  Ligand binding  
 The seven ErbB1 ligands (EGF, betacellulin, amphiregulin, TGF-α, heparin-
binding-EGF, epiregulin, and epigen) share sequence and structural homology, and each 
binds to unique but overlapping subsets of ErbB receptors (Jones, et al., 1999) (Schneider 
& Wolf, 2009).  The pairwise primary amino acid sequence identities for the soluble 
forms of the seven EGF-like ligands range from 29% to 53%, with most falling between 
40-45%. (Figure 4.2).  The reported affinities of each ligand for their receptors span 
several orders of magnitude, ranging from ~1 nM to >1 μM depending on the receptor-
ligand interaction in question (Jones, et al., 1999).  Interestingly, there does not appear to 
be a direct correlation between ligand-binding affinity and receptor activation.  For 
instance, epigen (EPG) stimulates robust ErbB1 activation and cell proliferation even 
though EPG binds to ErbB1 with >1 μM affinity (Kochupurakkal et al., 2005).  
Furthermore, it is unclear how such differences in binding affinity relate to the wide 
range of reported phenotypes in genetic experiments. 
 We thus set out to investigate the effects of the binding of different ligands upon 
receptor dimerization.  We report quantitative FRET measurements of ErbB1 dimer 
formation in plasma membrane-derived vesicles as a function of receptor binding to three 
ligands: EGF, epigen (EPG) and epiregulin (EPR).  Our results provide evidence that 
EGF induces receptor dimerization to a greater extent than either EPR or EPG, even 




observations may explain the unique signaling properties of EPG and EPR, suggesting 
that EPG and EPR may act as partial agonists for ErbB1 activation.  
Results  
Since the different ErbB ligands possess unique receptor binding characteristics, 
we reasoned that they might also induce dimer formation to differing extents.  To test this 
hypothesis, we employed QI-FRET microscopy to measure ErbB1-ECDTM-fp self-
association as a function of both ligand identity and ligand concentration (Fig. 4.1.A).  
We observed that all three ligands (EGF, EPG, and EPR) induced dimerization of ErbB1-
ECDTM-fp (Fig. 4.1), albeit to differing degrees.  At saturating concentrations of EGF 
(0.1 μM), ErbB1-ECDTM-fp formed constitutive dimers (Fig. 4.1A), whereas both 
epigen (EPG) and epiregulin (EPR) induced only partial receptor dimerization, even at 
saturating ligand concentrations (20 μM Fig. 4.1C-D).  Even at intermediate ligand 
concentrations (1 μM), binding to EPG and EPR induced receptor dimerization to a 
greater degree than was observed in the absence of ligand.  Interestingly, the FRET 
within a receptor dimer (intrinsic FRET, Ẽ) was not significantly different between the 
three ligands.  Thus, when compared to EGF, EPG and EPR appear to affect the 
receptor’s homo-dimerization propensity but not the separation distance between the C-
terminal ends of the TM domains within the ErbB1 dimer itself (Table 4.1). 
Discussion 
The differences in the reported EGF, EPG and EPR affinities for ErbB1 likely 




10 nM affinity for the ErbB1 extracellular domain, whereas EPG and EPR bind with ~1 
μm affinity (Jones, et al., 1999) (Bessman, et al., 2014) (Kochupurakkal et al., 2005).  
Assuming that binding of EPG and EPR to ErbB1 is saturated at 20 μm ligand 
concentration, this implies that binding of ErbB1 to EPR and EPG influences receptor 
dimerization in some other way than simple occupation of the ligand binding site on 
ErbB1.  Ligand binding can influence receptor activity in two possible ways.  First, 
ligand binding might alter the structural ensemble. The intrinsic FRET values for each 
ligand-induced dimer fall within experimental error (Table 4.1), indicating that the 
average separation distance between the C-terminal ends of ErbB1 does not differ 
significantly, though we note that our FRET assay does not report on the conformation of 
the ECD.  Second, since ligand binding and ErbB1 dimer formation are coupled 
equilibria, any differences in ligand binding affinity will alter the receptor dimerization 
coefficients as well.  It is possible that the combined effect of structural and 
thermodynamic perturbations produces the apparent differences in receptor dimerization 
observed here. 
Our results further suggest that the unique signaling properties of each ligand 
might be ascribed to their unique potentials for inducing ErbB1 dimer formation, though 
the precise mechanism in which ligand binding alters this equilibrium remains has not 
been investigated.  ErbB dimer formation certainly promotes receptor activation, but the 
relationship between these two phenomena remains unclear (see Chapter 3) (Bessman, et 
al., 2014).  Ligand binding may stabilize slightly different ECD conformations; even a 1-




when extended to the contact regions at the ends of domains II and IV, which in turn 
could affect the stability of the receptor dimer.  The observation that epigen induces 
ErbB1 dimerization to a lesser extent than EGF may explain its unique effects on ErbB1 
signaling.  For instance, epigen-bound receptors exhibit decreased ubiquitylation and 
degradation, which has been proposed to explain the apparent enhancement of signaling 
behavior.  Monomeric receptors are less likely to become activated than dimeric ones, 
and might thus be less susceptible to activation-induced ubiquitylation.  We note, 
however, that these studies were performed on truncated receptors which lacked their 
intracellular domains (ErbB1-ECDTM-fp).  The full length ErbB1 forms ligand-
independent dimers at a lower concentration threshold than the ECDTM variant.  The 
apparent differences in dimer induction for EGF, EPR and EPG reported here should thus 
be viewed as qualitative indicators.  Further studies using full length ErbB1 will be 
required in order to fully assess the differences between the three ligands. 
Lastly, we note that the experiments presented here only measure receptor dimer 
formation.  Our analysis assumes a two state system, when in reality ligand binding and 
ErbB1 dimerization are coupled to each other. Ligand may bind to both ErbB1 monomers 
and singly-liganded ErbB1 dimers, each of which may be described by a unique 
equilibrium constant.  In the same way, both liganded and unliganded ErbB1 dimers may 
exhibit unique dimerization coefficients.  A full understanding of the relationship 
between the two processes requires parallel observation of ErbB1 dimer formation as 
well as ligand binding (Macdonald & Pike, 2008).  The trends observed here should 




Figure 4.1. Epigen and epiregulin induce partial ErbB1 dimerization 
 
Figure 4.1. Corrected FRET as a function of concentration, measured from CHO cell 
vesicles expressing.  (A) Schematic of ErbB1-ECDTM-fp constructs used in (B-D).  
Vesicles were incubated with either no ligand, EGF, epigen (EPG) or epiregulin (EPR). 




circles) of 0.1 μM EGF.  Lines indicate the best fit to the dimerization model.  (C-D) 
Comparison of ligand-independent, EGF-induced, EPG-induced, and EPR-induced 
dimerization.  (C) EPG was assayed at 20 μM (royal blue) and 1 μM (light blue).  (D) 
EPG was assayed at 20 μM (royal blue) and 1 μM (light blue).  In C-D, the best fit for 
ligand-independent (black line) and EGF-dependent (green line) dimerization are 

















Figure 4.2. Primary sequence analysis of the seven EGF-like ligands 
 
Figure 4.2. (A) Multiple sequence alignment from the MUSCLE server 
(http://www.ebi.ac.uk/Tools/msa/muscle/).  The sequences represent the soluble EGF-
like domains of the mature growth factor proteins.  (B-C) Pairwise sequence alignments 
were performed using the EMBOSS server 
(http://www.ebi.ac.uk/Tools/psa/emboss_water/).  The identity/similarity matrices are 
colored according to the degree of identity/similarity, with green indicating 0%, yellow 
indicating 50% and red indicating 100%.  Abbreviations: EGF, epidermal growth factor; 
AREG, amphiregulin; BTC, betacellulin; EPG, epigen; EPR, epiregulin; HB-EGF, 





Table 4.1. Table of best fit parameters to a monomer-dimer equilibrium 
 
Table 4.1. The data in figure 4.1 were fit to the monomer dimer equilibrium described in 
Chapter 3 (see Materials and Methods).  The best fit parameters (Kapp and Intrinsic 
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